ACADIA Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACAD Nasdaq 2834 https://acadia.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ACADIA Pharmaceuticals Inc

Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment - Mar 13th, 2023 4:56 pm
Acadia’s rare-disease drug to cost $575,000 to $595,000 - Mar 13th, 2023 4:11 pm
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older - Mar 11th, 2023 2:45 am
1 Top Biotech Stock to Buy in March - Mar 7th, 2023 2:45 pm
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2022 Earnings Call Transcript - Mar 2nd, 2023 10:45 am
ACADIA Pharmaceuticals Full Year 2022 Earnings: EPS Misses Expectations - Mar 1st, 2023 10:41 am
Analysts See Steady Growth For Acadia Pharma's Nuplazid - Feb 28th, 2023 9:00 pm
Q4 2022 ACADIA Pharmaceuticals Inc Earnings Call - Feb 28th, 2023 2:26 pm
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates - Feb 27th, 2023 10:25 pm
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Feb 27th, 2023 9:05 pm
Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Feb 20th, 2023 3:00 pm
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 - Feb 14th, 2023 9:05 pm
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 13th, 2023 9:15 pm
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development - Jan 9th, 2023 2:00 pm
Investors in ACADIA Pharmaceuticals (NASDAQ:ACAD) from three years ago are still down 62%, even after 4.1% gain this past week - Jan 3rd, 2023 4:58 pm
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics - Jan 3rd, 2023 2:00 pm
Acadia Pharmaceuticals Bulls Will Need to Be Patient for Now - Jan 3rd, 2023 1:28 pm
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 - Dec 21st, 2022 9:05 pm
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Nov 8th, 2022 9:05 pm
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss - Nov 3rd, 2022 4:23 pm